The oral bioavailability of DNDI-VL-2098 was good to excellent in all four

species ( Table 2). DNDI-VL-2098 showed close to dose proportional exposures in rodents (Table 2). Oral exposure in hamster and mouse were determined across the 6.25–50 mg/kg range (doses tested for efficacy) using formulations identical to those used in efficacy studies. In both species, bioavailability was 100% at the lowest 6.25 mg/kg dose, and in both species an 8-fold increase in dose (from 6.25 to 50 mg/kg) led to an 11-fold increase in exposure. In NSC 683864 manufacturer rat, oral exposures were determined across the 5–500 mg/kg dose range (doses tested in early safety studies) using a suspension in CMC. Here, a 100-fold increase in dose led to about a 100-fold increase in exposure. Fig. 3a summarizes the relationship between dose and dose-normalized AUCs (DNAUC) in various species following suspension administration. The dose-normalized AUCs of DNDI-VL-2098 were generally independent

(within 2-fold) see more of the administered doses. In the rat and dog, oral solution and suspension exposures were determined at 5 mg/kg. In both species, the mean solution exposure was higher than that with suspension (Fig. 3b). In the dog at the higher dose of 50 mg/kg given as suspension, exposure did not increase proportionally (Table 2). A similar “apparent solubility limited absorption” did not occur in the rat where exposures increased dose-proportionally up to 500 mg/kg given as suspension. This observation is consistent with DNDI-VL-2098 being a low solubility/high permeability compound, with the high permeability overriding any limitation that low solubility may pose to absorption, at least in the rat. Because exposures increased proportionally with dose in the rat at high doses, follow up studies were performed in the dog at higher doses using a corn oil formulation.

As solubility of DNDI-VL-2098 was less in water, an oil-based formulation using corn oil was evaluated. In this case, a 100-fold increase in dose from 5 mg/kg to 500 mg/kg, led to a 37-fold increase in exposure (AUClast). By using a 500 mg/kg BID dosing (dosed 8 h apart; total dose 1000 mg/kg), there was found a 50% increase in exposure (360 ± 36 μg h/mL; n = 3) compared to that obtained at the 1250 mg/kg QD dose (246 ± 74 μg h/mL; n = 3, Fig. 4). The preclinical PK parameters were used to perform allometric scaling to predict pharmacokinetics in humans. First, simple allometric scaling of the clearance and volume of distribution data was performed using Y = aWb, where Y is the parameter of interest, and a and b are coefficient and exponent of the allometric equation, respectively, and W is body weight. The clearance exponent calculated with this approach was 0.9. Because it exceeded 0.7, the maximum lifespan potential (MLP (years) = (185.4) (Br0.636) (BW−0.225)) approach was used ( Mahmood, 2007). The MLP method gave estimates of 1.